Pharmaceutical company Allergan has received a positive opinion from Sweden’s Medical Products Agency (MPA) for Belkyra (deoxycholic acid) to treat moderate to severe convexity related to submental fat in adults when it affects patients psychologically.

Submental fullness or double chin is an undertreated condition whereby fat grows under the chin or neck of a person, thereby often giving an older or heavier look.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Allergan Research and Development (R&D) chief officer David Nicholson said: "We are delighted to receive the positive opinion from the Swedish Medical Products Agency (MPA) for Belkyra, which provides men and women who are bothered by submental fullness with a new minimally invasive treatment option.

"Because of the extensive evidence behind the product, we see Belkyra as a breakthrough treatment that will complement other aesthetic treatments."

"Because of the extensive evidence behind the product, we see Belkyra as a breakthrough treatment that will complement other aesthetic treatments."

On receiving approval, Belkyra will be the first prescription medicine to be licensed in Europe for the treatment of double chin.

See Also:

Belkyra is currently being assessed through the Decentralised Procedure, with the Swedish MPA acting as the reference member state for 20 other countries in the European Union (EU), along with Iceland and Norway.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Fullness under the chin or a double chin is wrongly believed to appear only on those who are overweight, whereas, in reality a person with any body type may have a double chin.

Double chin can also be related to aging, genetics or weight gain.

As a next step, Allergan will work to receive the national marketing authorisations in the concerned member states.

Belkyra is already licensed for use within Canada and the US as Kybella.